IBI-939
Advanced Solid Tumors
Phase 2Active
Key Facts
About Innovent Biologics
Innovent Biologics' mission is to develop and commercialize high-quality, innovative medicines that are affordable and accessible to patients worldwide. Its key achievements include a successful 2018 Hong Kong IPO, the commercialization of multiple blockbuster products like Tyvyt® (sintilimab), and the establishment of a deep, diversified pipeline through internal R&D and strategic partnerships. The company's strategy hinges on full integration, global expansion, and leveraging its robust technology platforms to deliver a sustainable portfolio of novel biologics.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |